Skip to main content

Table 1 Outcome according to clinical characteristics in the 100 PDAC patients enrolled in the present study

From: Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer

Characteristics N (=%) OS months
(95% CI)
P
No. patients All 100 14.0 (12.1–15.8)  
Age, years ≤65 43 15.2 (13.3–16.8) 0.361
  >65 57 14.1 (11.1–17.0)  
Sex Male 47 13.0 (11.1–14.9) 0.814
  Female 53 15.0 (11.9–18.1)  
Resection status R0 56 15.2 (12.3–21.6) 0.474
  R1 44 13.5 (11.2–31.0)  
Lymph node No 10 18.5 (7.6–32.4) 0.521
  Yes 90 14.2 (12.2–15.9)  
Grading 1–2 36 15.5 (11.5–18.1) 0.097
  3 64 12.1 (8.4–15.8)